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Abstract The severe acute respiratory syndrome (SARS) has
been one of the most epidemic diseases threatening human
health all over the world. Based on clinical studies, SARS-
CoV (the SARS-associated coronavirus), a novel coronavirus,
is reported as the pathogen responsible for the disease. To date,
no e¡ective and speci¢c therapeutic method can be used to treat
patients su¡ering from SARS-CoV infection. RNA interference
(RNAi) is a process by which the introduced small interfering
RNA (siRNA) could cause the degradation of mRNA with iden-
tical sequence speci¢city. The RNAi methodology has been used
as a tool to silence genes in cultured cells and in animals. Re-
cently, this technique was employed in anti-virus infections in
human immunode¢ciency virus and hepatitis C/B virus. In this
study, RNAi technology has been applied to explore the possi-
bility for prevention of SARS-CoV infection. We constructed
speci¢c siRNAs targeting the S gene in SARS-CoV. We dem-
onstrated that the siRNAs could e¡ectively and speci¢cally in-
hibit gene expression of Spike protein in SARS-CoV-infected
cells. Our study provided evidence that RNAi could be a tool for
inhibition of SARS-CoV.
, 2004 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
SARS-CoV (the SARS-associated coronavirus), which
causes the severe acute respiratory syndrome, threatens the
health of populations throughout the world [1,2]. Although
SARS is reported [3^7] as a novel coronavirus, it retains sim-
ilar protein structures as other members of the coronavirus
family [8].
The Spike protein of the coronavirus, with a molecular
weight of 150 kDa, contains a large amino-terminal ectodo-
main and short carboxy-terminal endodomain bridged with a
transmembrane domain. The ectodomain of the Spike protein
is extensively glycosylated with N-linked glycosylation and
seems important for the interaction with the receptors on the
surface of the host cells. The conformation change through
dimerization of the Spike protein is reported to be critical for
the fusion event between the viral envelope and cellular mem-
brane for the coronavirus family [9]. Therefore, binding of
antibody to the Spike protein could block the viron entrance
into host cells for some of the coronaviruses.
RNA interference (RNAi) (for reviews see [10^14]) is an
innate cellular process, which is activated by a double-
stranded RNA molecule with 19^23-nucleotide duplexes in
cells from Caenorhabditis elegans to mammals [15]. The
RNAi is triggered by degradation of single-stranded RNAs
of identical sequences. Therefore, RNAi technology can be
used to silence gene expression by directly targeting its speci¢c
sequence of mRNA. Beside the widely used strategies for
knocking down gene expression in academic research, RNAi
technology, generated by small interfering RNAi (siRNA),
has been used in therapeutic studies of human diseases includ-
ing cancer, neurogenerative diseases and viral infectious dis-
eases (reviewed in [14]).
To date, RNAi technology is reported as an ideal tool to
inhibit infectious virus replication in host cells because siRNA
can target and silence the important genes of the virus [16].
Using poliovirus as a model, Gitlin et al. [17] demonstrated
that siRNA could e¡ectively protect human cells against in-
fection by a rapidly replicating and highly cytolytic RNA
virus. Hu et al. [18] reported that siRNA could block retro-
viral infection in chick embryos and inhibit the growth of the
Rous sarcoma virus and human immunode¢ciency virus
(HIV) in cell culture. They found that the siRNA primarily
prevented accumulation of the viral RNAs synthesized in the
late stage of the infection, but did not degrade the RNA ge-
nome in the virus in the early stage of the infection. Other
groups reported that siRNA could speci¢cally inhibit HIV-1
replication and virus propagation [19] through targeting ma-
jor genes in the HIV life cycle, including p24 (the HIV long
terminal repeat) [20,21], vif, nef [19], tat and rev [22,23].
RNAi has been also used in anti-hepatitis C or B virus
(HCV, HBV), which causes chronic liver disease including
cirrhosis and hepatocellular carcinoma [24^28]. Papadia et
al. [28], using a cell culture system, showed that the siRNAs
generated from the HCV replicon could inhibit the HCV
mRNA transcripts and protein expression. Those siRNAs
could even inhibit HCV cDNA copies and OAS gene expres-
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sion, which was induced by interferon-K in virus-infected host
cells. Recently, McCa¡rey et al. [26] reported that RNAi
could be used in a mouse model to inhibit HBV replication.
To search for a potential therapeutic method to prevent
SARS-CoV infection, we adopted RNAi technology based
on reported studies in other infectious diseases. In this report,
we targeted the Spike protein of SARS-CoV using siRNAs
generated from the DNA vector. We demonstrated that the
siRNA could e¡ectively and speci¢cally silence gene expres-
sion of the Spike protein in SARS-infected cells.
2. Materials and methods
2.1. Vector construction
The vector with a U6 promoter (pBS/U6, a gift from Dr. Yang Shi
at Harvard Medical School, Boson, MA, USA) was used to construct
a 22 bp siRNAs. The hairpin cDNAs were generated through anneal-
ing of the complementary oligos synthesized, where ApaI and EcoRI
sites were constructed. The hairpin cDNA insert was subcloned into
the pBS/U6 vector through ApaI and EcoRI sites. The clones were
veri¢ed by XhoI digestion. Finally the clones were sequence-con-
¢rmed.
The full length cDNA of the Spike protein was subcloned into a
pCMV-Myc expression vector (Invitrogen) with BamHI and EcoRI
through polymerase chain reaction (PCR) generating restrictive en-
zymes in the 5P and 3P ends of the insert. The subcloned vector,
pCMV-Myc/HA-Spike, was sequence-con¢rmed for the correct frame
in the expression vector. pEGFP-N1 was from Clontech Laboratories.
2.2. Cell culture and transfection
Human embryonic kidney cell line 293T and African green monkey
kidney cell line Vero E6 were cultured in Dulbecco’s modi¢ed Eagle’s
medium (DMEM) supplemented with 10% heat-inactivated fetal bo-
vine serum (FBS), 100 U/ml penicillin and 100 Wg/ml streptomycin.
293T cells were plated onto 6 well plates at a density of 4U105 cells
per well and cultured at 37‡C with 5% CO2 overnight for transfection.
A total amount of 5 Wg DNA per well was used for transient trans-
fection with CalPhos (Clontech) according to the manufacturer’s pro-
tocol. Vero E6 cells were plated onto 12 well plates at a density of
2U105 cells per well and cultured at 37‡C with 5% CO2 overnight.
The transfection was performed at 90% cell con£uence with a total
amount of 4 Wg DNA per well using Lipofectamine 2000 (Invitrogen)
following the manufacturer’s protocol.
2.3. SARS-CoV culture and infection
SARS-CoV (strain BJ01, GenBank accession number AY278488),
provided by the Institute of Microbiology and Epidemiology, AMMS,
China, was propagated on Vero E6 cells. The virus was released from
the infected cells by three freeze^thaw cycles. The titration of the virus
was determined by plaque assay on Vero E6 cell monolayer. For the
test of inhibition of the virus by siRNA, 2U105 transfected Vero E6
cells (with siRNA vectors) were infected with 5U105 multiplicity of
infection (MOI) of SARS-CoV (BJ01), in a ¢nal volume of 1 ml of
DMEM with 2% FBS for 2 h at 37‡C. Cells were then washed once
with phosphate-bu¡ered saline (PBS, pH 7.4), before adding 2 ml
complete medium to allow growth for 48 h at 37‡C with 5% CO2.
All those operations were performed in a bio-safety P3 level lab.
2.4. Western blot
Cells overexpressing hemagglutinin (HA)-tagged Spike protein were
harvested 48 h post transfection and lysed with 0.3 ml of cold lysis
bu¡er (20 mM Tris^HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1%
Triton X-100, 1 mM NaVO3, 2.5 mM sodium pyrophosphate, 1 mM
L-glycerol phosphate, 1 mM phenylmethylsulfonyl £uoride, 5 Wg/ml
aprotinin, and 5 Wg/ml leupeptin, pH 7.5). 30 Wg of total protein from
cell lysate was separated on 6% sodium dodecyl sulfate^polyacryl-
amide gel electrophoresis, electro-transferred to nitrocellulose mem-
brane (Hyclone ECI, Amersham Pharmacia Biotech). Antibodies di-
rectly to HA, enhanced green £uorescent protein (EGFP) and L-actin,
obtained from Santa Cruz, were used to blot the membranes accord-
ing to the conditions the manufacturer provided. The signals were
detected by enhanced chemiluminescence (ECL, Amersham).
2.5. Immunostaining
Transfected cells were incubated for about 24 h. Cells were ¢xed in
4% paraformaldehyde for 20 min at room temperature, and permea-
bilized with PBS containing 0.2% Triton X-100 for 10 min. The cells
were blocked with FDB (PBS with 1 mM CaCl2, 1 mM MgCl2, 5%
normal goat serum, 10% fetal bovine serum and 2% bovine serum
albumin) for 1 h, and were incubated with primary antibodies in
FDB for 3 h. After washing with PBS containing 0.1% Triton
X-100, the cells were incubated with suitable secondary antibodies
conjugated with £uorescent isothiocyanate (TRITC) for 1 h. Cells
were washed with PBS three times before observation. The results
were analyzed using a Nikon TE300 £uorescence microscope. Pictures
were taken with a CCD camera (SPOT, Diagnostic Instrument, USA)
equipped with a computer-based image acquisition system.
2.6. RNA isolation and reverse transcription (RT) PCR
Total RNA from the transfected cells or infected cells was extracted
using Trizol (Invitrogen). The PCR reaction was performed using the
One Step RNA PCR kit (Takara, Japan) with 1 Wg of total RNA for
each sample. 1 WM of forward primer (5P-TATAGGATCCCAC-
CATGTTTATTTTCTTATTATTTCTTAC-3P) and reverse primer
(5P-TATAGAATTCTGTGTAATGTAATTTGACACC-3P) was used
for the PCR reaction with 25 cycles of denaturation (94‡C, 30 s),
annealing (55‡C, 1 min) and extension (68‡C, 4 min). L-Actin (for-
ward primer, 5P-CAAGAGATGGCCACGGCTGCT-3P ; reverse
primer, 5P-TCCTTCTGCATCCTGTCGGCA-3P) was used as an in-
ternal control and the reaction conditions were 25 cycles of denatur-
ation (94‡C, 30 s), annealing (55‡C, 50 s) and extension (68‡C, 1 min).
2.7. Northern blot
Total RNA (10 Wg) from SARS-CoV-infected cells was fractionated
on a 1.3% formaldehyde-agarose gel and transferred to a nitrocellu-
lose membrane. Probe S-gene (1350^1950 bp from ATG from the
CDS of the S gene) was labeled with 32P using the Prime-a-Gene
kit (Promega) according to the manufacturer’s protocol. Hybridiza-
tion was performed at 68‡C for 2 h in hybridization bu¡er (Promega).
Membranes were washed three times in 2USSC with 0.1% sodium
dodecyl sulfate at 50‡C and autoradiographed by PhosphorImager
(DNA Storm, Amersham Pharmacia Biotech).
2.8. Virus titration
Vero E6 cells were infected with 4U103 MOI SARS-CoV (BJ01)
per well 48 h post transfection with plasmids including pBS/U6, pBS/
U6/GFPi and pBS/U6/S-RNAi1/2. The virus was allowed to infect the
cells for 2 h and then was completely withdrawn by washing with
PBS. After incubation for 72 h, the cells were lysed and assayed for
the level of virus (MOI) in 96 well plates.
3. Results
3.1. Selection of siRNA target sequences in mRNA of Spike
protein
The coronavirus Spike protein plays a critical role in virus
infection. Therefore, we chose the S gene as a target for inhi-
bition of SARS-CoV infection. To locate the target site of
siRNA in the SARS-CoV genome, we selected those sequen-
ces of 22 bp with the structure of AGN18TT. As an empirical
design, we preferably chose the sites with GC/AT ratios be-
tween 30% and 60%. Also we used the selected sequences to
search GenBank to con¢rm their speci¢city. In matching for
those criteria, two speci¢c target sequences were determined
and noted, S-RNAi1 and S-RNAi2. A schematic presentation
of the sequences is shown in Fig. 1A. Those two targeted
sequences in the Spike protein were at 1358^1376 and 3081^
3099 bp from the ¢rst ATG of the cDNA of the gene, which
were located in the S1 and S2 region of the protein, respec-
tively.
3.2. Construction of the vectors generating siRNA
Although siRNA could be chemically synthesized directly,
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the cDNA vector driven by a promoter is used in most cases
[14] for convenience and economy reasons. In this study, we
adopted the U6 promoter vector [29] and constructed a 22 bp
siRNA through the hairpin, which could be produced by the
DNA vector. The hairpin cDNAs were generated through
annealing of the complementary oligos synthesized, where
ApaI and EcoRI sites were constructed. The hairpin cDNA
as an insert was subcloned into pBS/U6 vector through ApaI
and EcoRI sites. The correct clones were veri¢ed by XhoI
digestion, which was replaced by the insert. Finally, the clones
were sequence-con¢rmed. The single-strand hairpin RNAs
generated from the vectors were predicted as in Fig. 1C.
3.3. Expression of Spike protein in cultured cells
To generate an in vitro expression system of the Spike pro-
tein from SARS-CoV, we adopted the mammalian cell culture
method. The cDNA encoding the Spike protein from SARS-
CoV was constructed into pCMV-Myc, a mammalian expres-
sion vector with a CMV promoter, which could drive the
expression of the Spike protein in cultured cells. To detect
the protein expression, the cDNA of Spike protein was tagged
with HA at the C-terminus (Fig. 2A, top panel). This con-
struct was transfected into 293T cells and the expression of
Spike protein was measured by Western blot. The data
showed that the vector could drive the expression of Spike
protein of SARS-CoV in the cells at a high level (Fig. 2,
top panel, lane 1) although the molecular weight of the ex-
pressed protein (s 90 kDa) was smaller than the predicted
one (105 kDa). To avoid di¡erent transfection e⁄ciencies,
we balanced the total amount of DNA with an EGFP expres-
sion vector. The data showed that the EGFP expressions were
very even (Fig. 2, bottom panel, lanes 1, 3, and 4) and L-actin
level showed equal loading of samples (Fig. 2, middle panel),
suggesting that the transfection experiments were controlled
under identical conditions. Taken together, we overexpressed
the Spike protein from SARS-CoV in 293T cells, which could
be used for the study of the gene silencing in the cultured cells.
3.4. Silencing of S gene expression in cells by siRNA
To determine whether the siRNA we generated could e¡ec-
tively reduce the expression of Spike protein in cultured cells,
we ¢rst transfected the siRNA vectors pBS/U6/S-RNAi1 and
pBS/U6/S-RNAi2 into 293T cells where Spike protein was
overexpressed. To show the speci¢city of the siRNA targeting,
we used EGFP as a control. From the data, it was clearly
demonstrated that pBS/U6/EGFP-RNAi could speci¢cally si-
lence the expression of EGFP protein in cells (Fig. 2, bottom
panel, lane 2). However, pBS/U6/S-RNAi1, pBS/U6/S-RNAi2
or the vector alone (pBS/U6) had no e¡ect on EGFP expres-
sion (Fig. 2, bottom panel, lanes 1, 3 and 4). Interestingly,
both pBS/U6/S-RNAi1 and pBS/U6/S-RNAi2 could speci¢-
cally impair the expression of Spike protein in cultured cells
(Fig. 2, top panel, lanes 3 and 4), while pBS/U6/EGFP-RNAi
or the vector did not (Fig. 2, top panel, lanes 1 and 2). Mean-
while, all of the constructs had no e¡ect on L-actin expression
(Fig. 2, middle panel). All these data suggest that siRNA
targeting of the Spike protein in SARS-CoV could block or
silence the expression of Spike protein in mammalian cells.
To show the silencing of the Spike protein in transfected
cells, we also performed an immunostaining experiment using
anti-HA antibody. Similarly, we assessed EGFP expression by
using £uorescence microscopy. The results showed that EGFP
proteins were highly expressed in cells transfected with the
expression vector in the presence of the co-transfected pBS/
U6 vector (Fig. 3a), pBS/U6/S-RNAi1 (Fig. 3e) and pBS/U6/
S-RNAi2 (Fig. 3g), but rarely expressed in cells in the pres-
ence of the co-transfected pBS/U6/EGFP-RNAi (Fig. 3c). In
contrast, Spike protein could be detected at levels similar to
the EGFP protein in the control panel (Fig. 3a,b). However,
when pBS/U6/S-RNAi1 (Fig. 3f) and pBS/U6/S-RNAi2 (Fig.
3h) respectively were transfected into cells, Spike proteins
were shown to be gradually reduced. These data suggest
Fig. 1. Target sites and vector information. A: Locations of siRNA
target sites. S1 and S2 represent the S1 and S2 regions of Spike pro-
tein respectively. The targeted sequences for siRNA design are
listed. B: Schematic of vector for generating siRNA. pBS/U6 pro-
moter, sequence generating siRNA hairpin and transcriptional ter-
minal signal are shown as indicated. C: Diagram of predicted struc-
ture of siRNAs from pBS/U6/S-RNA1 and pBS/U6/S-RNA2.
UUCAAGAGA was used to generate the hairpin loop, indicated as
a cycle.
Fig. 2. Inhibition of expression of the Spike protein. Transfected
siRNAs as indicated inhibited Spike protein expression. The Spike
protein tagged with HA at the C-terminus (HA-Spike) overexpressed
in the cells, which were co-transfected with the indicated plasmids,
was detected by Western blot using anti-HA antibody from the ly-
sates of the cells. L-Actin and EGFP were used as internal and posi-
tive controls.
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that pBS/U6/S-RNAi1 and pBS/U6/S-RNAi2 signi¢cantly
blocked the expression of Spike protein in the cells, indicating
that the siRNAs we designed functioned in our mammalian
system.
To verify the inhibition of Spike protein expression by siR-
NAs through the inhibition of the S gene, semi-quantitative
RT-PCR was performed. The data show that pBS/U6/S-
RNAi1 and pBS/U6/S-RNAi2 reduced the accumulation of
mRNA S gene (Fig. 4, lanes 3 and 4 compared to lane 2)
while it had no e¡ect on L-actin mRNA. These data indicate
that siRNAs inhibited Spike protein expression through
blocking mRNA accumulation.
3.5. Inhibition of SARS-CoV infection by siRNA in cultured
cells
To determine whether the vector-based siRNA could e⁄-
ciently prevent SARS-CoV infection of cells, we transfected 2,
3 and 4 Wg of pBS/U6/S-RNAi1 (Fig. 5, lanes 3^5), and pBS/
U6/S-RNAi2 (Fig. 5, lanes 6^8) into Vero E6 cells in a 12 well
plate. As controls, the pBS/U6 vector alone (Fig. 5, lane 1)
and pBS/U6/EGFP-RNAi (as a non-related gene RNAi,
Fig. 5, lane 2) were also transfected into parallel cells. After
incubation for 1 day, the transfected cells were infected with
SARS-CoV (BJ01) at 5U105 MOI per well with 2U105 cells.
The cells were harvested and the total RNA was isolated for
RT-PCR to measure S gene expression. The data indicate that
both pBS/U6/S-RNAi1 and pBS/U6/S-RNAi2 could e¡ec-
tively inhibit gene expression of the Spike protein in the
SARS-CoV-infected cells (compare lanes 3 and 6 to lanes 1
and 2 in Fig. 5). As expected, with the increasing amounts of
siRNA transfected, there was increasing inhibition of S gene
expression (compare lanes 3^5 and lanes 6^8 in Fig. 5). Those
Fig. 3. Immunostaining for Spike protein in transfected cells. 293T cells were co-transfected with pCMV-Myc/HA-Spike and pEGFP-N1 vectors
for 48 h in the presence of di¡erent siRNA plasmids as indicated. The cells were immunostained with anti-HA antibody plus TRITC-conju-
gated secondary antibody (red). The pictures were viewed with a Nikon TE300 microscope and captured with SPOT CCD software. The
EGFP pictures were observed before immunostaining. The co-transfected vectors are (a,b) empty vector pBS/U6, (c,d) pBS/U6/EGFP-RNAi,
(e,f) pBS/U6/S-RNAi1, and (g,h) pBS/U6/S-RNAi2.
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data were recon¢rmed by Northern blots (Fig. 6, same design
as Fig. 5), suggesting that the siRNA we generated could
block S gene expression of SARS-CoV in the infected cells.
3.6. siRNA inhibited the replication of SARS-CoV from the
infected cells
Since SARS-CoV can replicate rapidly in cells we tested the
ability of siRNA to inhibit virus production. After 72 h of
culture, the virus in the medium of the cells should represent
the newly replicated virus in the cells. To validate the siRNA
e¡ects on replication of SARS-CoV, we performed virus titra-
tion assays by assaying for extracellular virus in infected cells
72 h post infection. The data showed that the control plate
had high titers of virus (Fig. 7, lane 1), suggesting the virus
replicated in the cells during the 72 h culture period. In con-
trast, the virus titer was dramatically decreased in the plate
where the cells were transfected with siRNA (Fig. 7, lanes 2
and 3), demonstrating that the siRNA inhibited virus replica-
tion. Both pBS/U6 and pBS/U6/EGFP-RNAi treatments had
similar levels of virus to that of the control, suggesting the
RNAi e¡ect was speci¢c.
4. Discussion
SARS-CoV has been classi¢ed as a novel member of the
coronavirus family with signi¢cantly di¡erent genome sequen-
ces [4,7,30]. However, the structure of the virus is similar to
the other coronaviruses, which contain a spike protein
thought to play an important role in viral entry and patho-
genesis [9]. In an attempt to prevent and inhibit SARS-CoV
replication, we employed RNAi technology, which has been
used to silence virus gene expression in HIV and HCV/HBV.
In this paper, we provide evidence that a DNA vector-based
siRNA could e¡ectively and speci¢cally inhibit gene expres-
sion of the Spike protein from SARS-CoV. Initially, we
showed that siRNAs silenced the expression of Spike protein
in cells transfected with S gene expression vector. Both West-
ern blot and immunostaining experiments consistently sug-
gested that the DNA vectors carrying the siRNA hairpin tar-
geted the overexpressed S gene in cells. We also showed that
Fig. 4. Reduced mRNA accumulation of the S gene in cells overex-
pressing Spike protein. 293T cells were co-transfected with the S
gene expression vector (pCMV-Myc/HA-Spike) and the indicated
plasmids for siRNA or control vectors. Cells were harvested after
transfection for 2 days. RT-PCR products for the S gene and the
internal control, L-actin, are shown as indicated molecular weights.
Fig. 5. Dose-dependent inhibition of S gene mRNA accumulation.
The Vero E6 cells were transfected with the indicated plasmids for
one day. Thereafter, the cells were infected with SARS-CoV (BJ01)
at 5U105 MOI/ml. After 2 days of infection, the cells were har-
vested with Trizol (Promega) for RNA isolation in a P3 lab. RT-
PCR was performed to show the accumulation of S gene mRNA
from the infected SARS-CoV. Increasing amounts of siRNA vectors
transfected are indicated. RT-PCR products for the S gene and the
internal control, L-actin, are shown as indicated molecular weights.
Fig. 6. Northern blot of S gene mRNA in the transfected cells. The
Vero E6 cells were transfected with the indicated plasmids and
treated with SARS-CoV as in Fig. 5. The total RNA was subjected
to Northern blot analysis with 32P-labeled probes ampli¢ed from
SARS-CoV cDNA (BJ01) and GAPDH. The abundance of S gene
mRNA and GAPDH is indicated.
Fig. 7. SARS-CoV titration in the medium of the infected cells. The
indicated Vero E6 cells were infected with SARS-CoV for 2 h and
then the virus was washed o¡ with medium. The virus titrations
were determined for the supernatant (medium) of the infected cells
cultured for 72 h after infection. (+) indicates cells infected with
SARS-CoV, (3) indicates normal cultured cells.
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the mRNA level was decreased when siRNAs were transfected
into the cells. This model system demonstrated the inhibition
of gene expression of the virus as in the case of inhibition of
HIV and HCV/HBV [18,19,21^23,27,28,31^33].
The genome sequence revealed SARS-CoV as a novel co-
ronavirus, in which the typical Spike protein and other pro-
teins were predicted. However, there is no report on the iso-
lation and puri¢cation of Spike protein from SARS-CoV-
infected cells or tissues. In this report we used the recombi-
nant Spike protein cDNA from the SARS-CoV genome and
expressed the protein in 293T cells. The molecular weight of
the expressed HA-tagged protein was smaller than the pre-
dicted one, suggesting the modi¢cation of Spike protein in
mammalian cells. Our data showed that this expression vector
could be targeted by the siRNAs. Because there is no anti-
Spike protein antibody generated, this is a direct way to detect
the inhibition of the protein expression by siRNA in cultured
cells.
Importantly, after demonstration that siRNAs inhibited
Spike protein expression in cells transfected with the expres-
sion vector, we used Vero E6 cells, which were reported to be
susceptible to SARS-CoV infection and replication. We in-
fected the cells with SARS-CoV (strain BJ01) and found,
through both RT-PCR and Northern blot, that siRNAs could
signi¢cantly inhibit S gene mRNA accumulation, suggesting
that siRNAs might inhibit SARS-CoV replication in cells.
This could be further demonstrated by the evaluation of the
virus yields from the cells. We consider that the virus in the
medium after 72 h of culture represents newly replicated virus.
Therefore, the decreased yields of virus in the medium con-
¢rmed that virus replication was inhibited by the siRNAs we
designed.
Taken together, we report that the designed siRNA vectors
targeting the mRNA of Spike protein from SARS-CoV could
speci¢cally and e¡ectively silence gene expression in mamma-
lian cells. This study provides evidence that siRNA could be
employed as a potential tool to inhibit gene expression of the
Spike protein of SARS-CoV. To our knowledge, this is the
¢rst report that siRNA could be used for inhibition of SARS-
CoV in cells. Whether those siRNAs could be used in animal
models for SARS-CoV infection is under investigation.
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